Compare Crispr Therapeutics AG (CRSP) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs The Coca-Cola Co K — how do they compare? Crispr Therapeutics AG trades at $50.52 (market cap $4.97B), while The Coca-Cola Co K trades at $82.91 (market cap $357.45B). The key difference: The Coca-Cola Co K is far larger — about 71.9× Crispr Therapeutics AG's market cap, and The Coca-Cola Co K pays a 2.55% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | KO | |
|---|---|---|
Market Cap | $4.97B | $357.45B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $84.25 |
52-Week Low | $44.34 | $65.67 |
Enterprise Value | $3.32B | $387.52B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Coca-Cola (KO) trades at $82.74, down 1.79% on the day, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with a 27.8% net income margin and consistent earnings beats in recent quarters. Analyst consensus is a Buy with a $89.75 price target, and recent news highlights institutional accumulation and steady demand trends ahead of Q2 2026 earnings.
The outlook remains positive given robust profitability, dividend growth history, and institutional support. Key risks include regional demand divergence and high debt levels. Upside potential exists if the stock approaches the consensus target, but macroeconomic headwinds could pressure near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
